Treatment response to spironolactone in patients with heart failure with preserved ejection fraction: a machine learning-based analysis of two randomized controlled trials.

Journal: EBioMedicine
Published Date: Sep 7, 2023

Abstract

BACKGROUND: Whether there is a subset of patients with heart failure with preserved ejection fraction (HFpEF) that benefit from spironolactone therapy is unclear. We applied a machine learning approach to identify responders and non-responders to spironolactone among patients with HFpEF in two large randomized clinical trials.

Authors

  • Karl-Patrik Kresoja
    Department of Cardiology, Heart Center Leipzig at University Leipzig, Leipzig, Germany.
  • Matthias Unterhuber
    Department of Cardiology, Heart Center Leipzig at University Leipzig, Leipzig, Germany.
  • Rolf Wachter
    Department of Cardiology and PneumologyUniversity of Göttingen Medical CentreGöttingenGermany; DZHK (German Centre for Cardiovascular Research), Partner Site GöttingenGöttingenGermany.
  • Karl-Philipp Rommel
    Department of Cardiology, Heart Center Leipzig at University Leipzig, Leipzig, Germany.
  • Christian Besler
    Department of Cardiology, Heart Center Leipzig at University Leipzig, Leipzig, Germany.
  • Sanjiv Shah
    Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, USA.
  • Holger Thiele
    Department of Cardiology, Heart Center Leipzig at University Leipzig, Leipzig, Germany.
  • Frank Edelmann
    Department of Internal Medicine and Cardiology, Campus Virchow Klinikum, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Philipp Lurz
    Department of Cardiology, Heart Center Leipzig at University Leipzig, Leipzig, Germany. Electronic address: Philipp.Lurz@medizin.uni-leipzig.de.

Keywords

External Resources

Popular Topics
Recent Journals